Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS, which is critical for the biology of PDA progression. Direct inhibition of KRAS through pharmacological means remains a challenge; however, targeting key KRAS effectors has therapeutic potential. We investigated the contribution of TANK-binding kinase 1 (TBK1), a critical downstream effector of mutant active KRAS, to PDA progression. We report that higher levels of TBK1 mRNA are associated with poorer overall survival in human PDA patients and that TBK1 supports the growth and metastasis of KRAS-mutant PDA by driving an epithelial plasticity program in tumor cells that enhances invasive and metastatic capacity. Further, we identify that the receptor tyrosine kinase Axl induces TBK1 activity in a Ras-RalB-dependent manner.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is a lethal and poorly understood human malignancy with patient survival that has not improved substantially in the last 40 years [1] . Each year, >45,000 new cases are diagnosed and an almost equal number of patients succumb to the disease [1] . The high incidence to death ratio is attributed to therapy resistance and to late diagnosis, at which point the tumor has metastasized [2] .
Significant effort has gone into identifying critical pathways for PDA growth that can be exploited therapeutically. Understanding the biology of activating point mutations in the small GTPase, KRAS, which is an early genetic event in human PDA development and is present in 90% of PDA cases [3] , has been a focal point of drug development strategies. Oncogenic KRAS is the dominant driver in PDA initiation and maintenance [4] ; however, RAS itself has not been an amenable target for direct inhibition. As a result, developing therapeutic strategies that inhibit RAS effector signaling is attractive [5] .
While the majority of RAS effector-targeted therapies are focused on the RAF and PI3K signaling networks, there is considerable evidence supporting the lesser studied, RALGEF-RAL effector pathway as a critical contributor to PDA growth [6] [7] [8] . Though not mutated as frequently as the RAF-MEK-ERK and PI3K signaling molecules in human cancer, the RALA and RALB GTPases of the RALGEF pathway are more consistently activated than RAF or PI3K in human pancreatic tumors [6] [7] [8] . The serine threonine protein kinase, TANK-binding kinase 1 (TBK1), is a major constituent of the RAL pathway and is critical to the development of Ras-driven cancers [9, 10] . Studies in lung cancer revealed that RALB activates TBK1, leading to the restriction of apoptosis, while having no effect on survival of non-tumorigenic epithelial cells [11] . Moreover, the expression of an oncogenic KRAS allele in TBK1-deficient murine embryonic fibroblasts was found to induce cell death, suggesting that TBK1 is integral for cells to tolerate transforming levels of oncogenic RAS [11] . The critical contribution of RALB and TBK1
to RAS-induced lung cancer growth was corroborated in an RNAi screen of synthetic lethal partners of oncogenic KRAS, where RALB and TBK1 were identified as top hits [10] .
Given the prominent activity of RalB in pancreatic cancer and the requirement of TBK1 for cells to tolerate transforming levels of oncogenic RAS, we hypothesized that TBK1 is critical to KRAS-driven pancreatic cancer growth. Here we show that TBK1 is expressed highly in pancreatic cancer and correlates with worse survival in human PDA patients.
We found that the loss of TBK1 kinase function in preclinical mouse models of KRASmutant PDA resulted in reduced tumor load and reduced metastatic events, indicating that TBK1 activity contributes directly to the aggressive properties of pancreatic cancer.
Taken together, our findings highlight TBK1 inhibition as a novel approach to targeting KRAS-mutant pancreatic cancer.
Materials and methods

Animals
NOD SCID mice were purchased from the UT Southwestern mouse breeding core (Dallas, TX). Tbk1 Δ/Δ , Tbk1 +/+ , Kras LSL-G12D/+ ; Cdkn2a Lox/Lox- (KI) and Cdkn2a Lox/Lox ; Ptf1a Cre/+ (IC) mice were generated as previously described [12] [13] [14] . : KPC mice. All mice were bred and maintained in a pathogen-free barrier facility with access to food and water ad libitum.
Tbk1
All protocols for mouse use and euthanasia were reviewed and approved by the institutional animal care and use committee of the University of Texas Southwestern
Medical Center (Dallas, TX).
Animal studies
All experiments were conducted using littermate-controlled mice. 
In vitro drug response assay
Assays were performed in 96-well format as described [19] . Briefly, cells were plated on day 0 and compound II [9] was added on day 1 in 4-fold dilutions starting at 20 µM 
Wound healing and invasion assays
Wound healing assays were conducted in 6-well plates. Monolayers of cells were grown in low-serum media until 90% confluency was reached. Each well was scratched with a 
Organotypic culture and immunocytochemistry
For each cell line, 2000 cells were plated in 8-well chamber slides onto a base layer of Matrigel (5 mg/ml) and collagen I (1.5-2.1 mg/ml) and cultured for 3 to 4 days in a humidified 37°C incubator as previously described [20] . For immunocytochemistry, cultures were fixed in 2% formalin (Sigma-Aldrich) in PBS for 20 min, permeabilized with 0.5% Triton X-100 in PBS for 10 min at room temperature, incubated with Alexa
Fluor 488 Phalloidin (A12379, Invitrogen) or Alexa Fluor 546 Phalloidin (A22283, Invitrogen) in immunofluorescence buffer as described [21] for 1 hour at room temperature and mounted using ProLong Gold antifade reagent with DAPI (Invitrogen).
Images were acquired using a confocal laser-scanning microscope (LSM880, Zeiss) through UT Southwestern's live cell imaging core (Dallas, TX) and a Nikon Eclipse E600 microscope with a Nikon Digital Dx1200me camera.
Active GTPase assays
Active RAS in cell lysates was measured via precipitation with GST-tagged RAF-RBD beads (Ras Pull-down Activation Assay Biochem Kit; Cytoskeleton, Denver, CO). Active RalB in cell lysates was measured via precipitation with RalBP1 PBD Agarose beads (Cell BioLabs, San Diego, CA). Lysates were prepared and precipitation was performed per manufacturer instructions. Subsequently, pull-down samples and respective whole cell lysates were immunoblotted with anti-RAS (pan) or anti-RALB (pan) and indicated loading controls.
Reagents
The mammalian expression plasmid pCDH-CMV-MCS-TBK1-EF1-NEO was generously provided by Drs. Peiqing Shi and James Chen (UT Southwestern Medical Center, Dallas, TX). Lentiviral-based expression constructs were packaged by co-transfection of HEK293T cells with psPAX2 and pMD2.G packaging system (4:2:1). Polyethylenimine (PEI) was used for transfection at a 3:1 ratio of total DNA. Transfection media was replaced with 10% complete DMEM 24 hours post transfection, and incubated a further 24 hours prior to viral particle collection. Tbk1 +/+ and Tbk1 Δ/Δ : KIC cells were seeded at a density of 1 x 10 6 cells per 10 cm dish. Twenty-four hours later, the cells were infected with lentiviral particles and polybrene (10 μg/ml). At 24 hours post infection, cells were given fresh medium containing G418 (400 μg/mL, InvivoGen) for selection and maintained in culture under selection for 3 weeks following initial infection. AF854 (R&D Systems, Minneapolis, MN) was previously shown to activate mouse Axl and was used at indicated concentrations to stimulate mouse Axl [22] . Compound II was synthesized by William G. Bornmann (UT MD Anderson Cancer Center) and found to be a potent inhibitor of TBK1 and IKKɛ in a chemical compound screen as previously described [9] .
Clinical data set
Gene expression data and survival analyses of 84 pancreatic cancer patients with annotated clinical outcomes were downloaded from the Cancer Genome Atlas. For survival analyses, gene expression data was divided into the top 25% and bottom 75%.
Cox regression was used to calculate hazard ratios and Kaplan-Meier survival analyses.
Significance for these plots was determined using the log-rank test.
Statistics
Statistical analyses were performed using GraphPad Prism (GraphPad, La Jolla, CA).
Results are expressed as mean ± SEM. All data were analyzed by t test. Significance was accepted at p < 0.05, with asterisks denoting p-value levels: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Results
TBK1 expression in pancreatic cancer
TBK1 is expressed in numerous epithelial tumors, including breast, lung, and colon [10, [23] [24] [25] . However, the function and activity of TBK1 in human pancreatic cancer has not been characterized extensively. We found that TBK1 was expressed and was active (pTBK1) under basal conditions in a panel of human KRAS-mutant PDA cell lines. In contrast, TBK1 was expressed but with reduced activity in normal pancreatic ductal epithelial cells (HPNE) [17] or KRAS wild-type PDA cells. Mouse embryonic fibroblasts isolated from Tbk1-mutant mice (Tbk1 Δ/Δ ) [12] served as a negative control with no detectable expression of TBK1 or pTBK1 (Fig. 1a) . Additionally, we observed higher TBK1 protein levels in spontaneous pancreatic tumors from genetically engineered mouse models (GEMMs) compared to normal pancreas from littermate controls (Fig.   1b) . We previously reported that TBK1 expression is associated with a poor prognosis in pancreatic cancer patients (stages I-II) from the Cancer Genome Atlas [26] . From this cohort (n = 84), gene expression was divided into top 25% and bottom 75% percentiles for Kaplan-Meier survival analyses. While expression of TBK1 homolog, IKBKE showed no correlation with survival, high expression of TBK1 showed a strong trend towards poorer overall survival in this patient cohort (p = 0.07) (Fig. 1c-d) . Though not causative, this data suggests that TBK1 expression and activity is important in human pancreatic cancer.
KRAS-driven pancreatic cancer growth is disrupted by restricting TBK1 kinase activity
After observing high TBK1 activity in human PDA cell lines with mutant active KRAS, we tested cell line dependency on TBK1 for viability using compound II, a 6-aminopyrazolopyrimidine derivative with an IC50 of 13 nM and 59 nM against TBK1 and IKKɛ, respectively [9] . Compound II has 100-to 1000-fold less activity against other purified recombinant protein kinases tested, including PI3K and mTOR family members [9] . Following a 96-hour exposure to compound II, the viability of human and mouse PDA cell lines was measured using a MTS assay (Fig. 2a) . Cell lines harboring a KRAS mutation (shown in red) segregated distinctly from wild-type KRAS cell lines (shown in blue) with an IC50 of ~1 μM versus greater than 5 μM, respectively. The KRAS wild-type PDA cell line, Hs766T, which previously showed no TBK1 activity (Fig. 1a) , was the least sensitive to TBK1 inhibition with an IC50 above 20 μM. In this panel, MCF-7 is a KRAS wild-type cancer cell line that was previously shown [9] to be less sensitive to compound II and therefore served as a negative control with an IC50 of 5 μM.
Additionally we tested two murine cell lines (KPC-M09 and Tbk1 +/+ : KIC-B) isolated from mutant Kras-driven PDA GEMMs that proved to be more sensitive to compound II than the human PDA cell lines. Tbk1 Δ/Δ : KIC-A cells were isolated from a PDA GEMM that lacks functional TBK1 and therefore served as an additional negative control with an IC50 of 7 μM. The selective sensitivity of mutant KRAS PDA cell lines to TBK1 inhibition in culture led us to speculate whether TBK1 was essential to RAS-driven PDA tumorigenesis in vivo.
To assess the contribution of TBK1 to PDA progression in vivo, we crossed Tbk1 mutant mice (Tbk1 Δ/Δ ) that harbor two copies of a null Tbk1 allele into a GEMM of PDA.
The "null" Tbk1 allele encodes a truncated TBK1 protein that is kinase-inactive and expressed at low levels, thereby allowing analysis of global TBK1 kinase loss in vivo [12] . (Fig. 2b-c, Supplemental Fig. 1a) . Malnutrition resulting from loss of normal exocrine pancreas function and pancreatic enzyme insufficiency contributes to early death in the KIC model [28] . Thus, we cannot exclude the possibility that the antitumor effects of Tbk1 loss are surpassed by the aggressiveness of the KIC model, causing the mice to succumb to malnutrition. Fig. 3a) . Low vimentin expression was confirmed at the protein level by immunofluorescent staining in tumors from 8-week-old animals (Fig. 3b) (Fig. 3c) .
Furthermore, we evaluated collagen deposition, a hallmark of pancreatic cancer that promotes EMT in PDA and is upregulated in response to epithelial plasticity [27, 29] . : KIC tumors by trichrome histology (Fig. 3d) .
To "cobblestone" morphology, a feature consistent with epithelial cells. These differences in morphology were observed in organotypic culture after the cells were plated on a mixed layer of collagen and Matrigel (Fig. 3e) . Evaluation of EMT-related markers revealed higher expression of epithelial proteins, ZO-1 and E-cadherin and lower expression of the mesenchymal proteins Vimentin, Slug and Snail in Tbk1 Δ/Δ : KIC cell lines (Fig. 3f) .
These results illustrate a unique epithelial signature in Tbk1 Δ/Δ : KIC cells and have implications for functional differences in tumor cell motility.
Tbk1 Δ/Δ : KIC tumor cells are less migratory and invasive
Epithelial plasticity changes commonly correspond with alterations in tumor cell motility and invasiveness [30] . (Fig. 4a) . For each cell line, migration at 24 hours was plotted against total cell population doublings (Fig. 4b) (Fig. 4c-d) . These results further highlight the reduced migratory ability of Tbk1 Δ/Δ : KIC cells.
Evaluation of Tbk1 loss on pancreatic cancer metastases
Next we asked whether the reduction in tumor cell motility with kinase-dead Tbk1 translated to fewer metastases in vivo. The KIC mouse model of PDA is an aggressive model with an average life span of ~10 weeks [13, 14, 27] . As such, these mice rarely develop gross metastases, making this model less than ideal for comparing metastatic burden. However, it's worth mentioning that livers from Tbk1 +/+ (n = 14) and Tbk1 Δ/Δ (n = 12) KIC mice were examined for micro-metastases using histology and qPCR. Lesions were identified in 6 livers from Tbk1 +/+ animals but no lesions were found in livers from
Tbk1-mutant mice (Supplemental Fig. 1b-d (Fig. 5a-d) .
While the experimental metastasis assay results were striking, the effect of Tbk1 loss on spontaneous metastatic development was also of interest. Therefore, we crossed (Fig. 5f ). Liver and lung metastases were evaluated grossly and by H&E, alcian blue, and CK19 immunohistochemical staining (Fig. 5g-h ).
As expected, ~40% of Tbk1 +/+ : KPC mice were positive for metastasis, but strikingly, no metastatic lesions were detected in Tbk1 Δ/Δ : KPC mice (Fig. 5g-h) (Fig. 6b, Supplemental Fig. 3) .
Further, Tbk1 Δ/Δ : KIC cell lines rescued with pCDH-TBK1 formed 2-3x as many lung tumor nodules, resulting in greater diseased lung burden than pCDH-empty vectorinfected cells after i.v. injection (Fig. 6c-f ). These results demonstrate that Tbk1 loss is responsible for the migratory and invasive deficiency in Tbk1 Δ/Δ : KIC cells and highlight a novel function for TBK1 in promoting a migratory program in tumor cells.
TBK1 is central to Axl-driven epithelial plasticity
Pancreatic tumor cells frequently exploit EMT programs during metastatic dissemination [30, 32] . However, the absence of functional TBK1 in pancreatic tumor cells limits EMT, invasion, and metastases. We recently reported that TBK1 is downstream of the receptor tyrosine kinase Axl, a receptor associated with EMT in PDA [18, 33] .
Pharmacological inhibition of Axl led to a concentration-dependent decrease of TBK1 activity while the stimulation of Axl with its ligand, Gas6, resulted in TBK1 activation [18] . To determine if TBK1 is central to Axl-driven EMT, we evaluated Axl signaling in KIC tumor cells (Fig. 7a) (Fig. 7b) . Previous work has shown a RalB GTPase-mediated activation of TBK1 [11] ; therefore, we tested if Axl-induced activation of RAS could increase GTPbound RalB, mediating the activation of TBK1. Tbk1 +/+ : KIC-A cells treated with AF854
showed a 3-fold increase in RalB-GTP, demonstrating that RalB activity is increased upon Axl activation (Fig. 7c) . Axl-induced Ras and RalB activation was validated in an additional murine PDA cell line, KPfC-8, derived from a spontaneous tumor in the KPfC (Kras LSL-G12D/+ ; Trp53 lox/lox ; Ptf1a Cre/+ ) GEMM of PDA (Fig. 7d) . To extend and confirm these findings in human pancreatic cancer, we stimulated Panc-1 cells with Gas6, which we previously demonstrated increases TBK1 activity [18] , and detected an increase in GTP-bound Ras and RalB (Fig. 7e) . These results are the first to show that Axl activates RAS and RalB, which leads to downstream activation of TBK1 and AKT, ultimately resulting in increased EMT and a more aggressive and metastatic tumor cell phenotype (Fig. 7f) .
Discussion
Activating mutations in KRAS are the dominant oncogenic drivers of pancreatic cancer [3, 4] . No other common epithelial cancer has a single gene with comparable mutation
frequency, yet efforts to therapeutically target mutant RAS proteins have not been successful [5] . However, targeting signaling components downstream of RAS that are required for RAS-mediated oncogenesis presents a viable therapeutic alternative [34] .
TBK1 is a crucial effector of mutant active KRAS that we found to be expressed abundantly in KRAS-mutant PDA tumors and cell lines. TBK1 expression correlated negatively with survival in human pancreatic cancer patients. In addition, the pharmacological inhibition of TBK1 with the selective inhibitor compound II was found to It is estimated that nearly 90% of cancer mortalities are due to metastases [35] , yet TBK1 studies to date have evaluated the effect of TBK1 inhibition only on primary tumor burden. EMT is a hallmark of metastasis in pancreatic cancer and is critical to cancer cell dissemination [36] [37] [38] . Within this morphological cellular program, epithelial cancer cells lose contact with the basement membrane and neighboring cells while gaining a more mesenchymal and invasive phenotype [36, 39] . Our results show that tumors and isogenic cell lines from the KIC pancreatic GEMM that lack functional TBK1 are more epithelial in gene expression and morphology than KIC tumors containing wild-type
Tbk1. These findings, in combination with mechanistic studies demonstrating that TBK1
is downstream of the EMT driver Axl, indicate that EMT in pancreatic tumor cells is halted by Tbk1 loss. TBK1 has been linked to EMT in other cancer types. In contrast to our results, knockdown of TBK1 in ERα-positive breast cancer cells reportedly induced EMT and enhanced tumor growth and lung metastasis by suppressing ERα expression [23] . However, in two separate recent studies, gene expression analysis revealed that a mesenchymal gene signature in melanoma and non-small cell lung cancer (NSCLC) cell lines was associated with sensitivity to TBK1 inhibition (TBK1i) [40, 41] . Further analysis revealed mutations in RAS family members as a common feature of NSCLC cell lines that showed sensitivity to TBK1i while NSCLC cells that were resistant to TBK1i had a more epithelial gene expression profile and less frequent activating RAS mutations [40] .
The mesenchymal gene signature in TBK1i-sensitive NSCLC lines is consistent with our observations in KRAS-driven Tbk1 +/+ : KIC tumors that have undergone EMT. Moreover, the epithelial gene expression profile of TBK1-resistant NSCLC cells lines matches the epithelial phenotype of Tbk1 Δ/Δ : KIC tumors that grew independent of TBK1. Though the precise mechanism of how TBK1 promotes EMT is unclear, TBK1 can directly activate AKT [9] . AKT activation can drive EMT via the induction of Snail and Slug that transcriptionally repress E-cadherin and induces Vimentin, Twist1, MMP-2, and MMP-9
that promote tumor cell invasion [39, 42, 43] . Current studies are focused on understanding the interaction between TBK1 and AKT driving the mesenchymal phenotype in PDA and the identification of additional TBK1 substrates that promote EMT programs.
Interestingly, Tbk1-mutant PDA tumors were smaller than Tbk1 wild-type tumors, indicating that Tbk1 loss affects primary tumor growth in addition to tumor cell motility.
TBK1 is central to numerous biological processes that could affect the growth of the primary tumor, including cell division, autophagy, innate immune response, and AKT/mTOR signaling [26, 40, 41, [44] [45] [46] [47] [48] [49] . In the context of pancreatic cancer, TBK1 has been reported to promote basal levels of autophagy as a means of silencing cytokine production [48] . These findings imply that the inhibition or loss of TBK1 in PDA could increase cytokine production, ultimately driving immune activation and potentially an antitumor immune response. shown to produce higher levels of pro-inflammatory cytokines in response to immune challenge [12] . In agreement with the notion that Tbk1 loss produces antitumor immunity, two recent studies reported that immune evasion and metastatic behavior are highly associated with the engagement of the cGAS-STING-TBK1 innate immune pathway in cancer cells [50] [51] [52] . In the first study, Backhoum et al. [51] found that chromosomal instability in cancer cells, caused by errors in chromosomal segregation during mitosis, promoted cellular invasion and metastasis through the introduction of double-stranded DNA into the cytosol, engaging the cGAS-STING-TBK1 antiviral pathway. In the second report, Cañadas et al. [52] characterized an interferonstimulated positive feedback loop of antisense endogenous retroviruses (ERVs) present in a number of human cancer cell lines that produced hyperactive innate immune signaling, myeloid cell infiltration, and immune checkpoint activation. Additionally, they discovered that high ERV-expressing cancer cells correlate with an Axl-positive mesenchymal state, which is consistent with our observations [52] .
An important consideration with our Tbk1 Δ/Δ PDA models is that the global Tbk1 Collectively, these observations support a pro-tumor immune function for TBK1 that could contribute to the larger tumor sizes in Tbk1 wild-type PDA mice.
Going forward, it will be important to understand the unique function of TBK1 in each relevant cell type within a tumor. Here we provide evidence of the effects of global Tbk1 loss in all cell types with our Tbk1 Δ/Δ PDA models, which in many respects is biologically analogous to the effects of pharmacologically inhibiting TBK1 systemically. Overall, our findings expand the spectrum of biological activities of TBK1 and suggest that the therapeutic inhibition of TBK1 may be a useful strategy to control tumor cell invasion and resulting metastases in RAS-driven cancers.
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